Immuron (ASX:IMC) Announces First USA Orders For Travelan
Melbourne, April 20, 2015 - (ABN Newswire) - Australian biopharmaceutical company Immuron Limited (ASX:IMC) (OTCMKTS:IMROY), manufacturer of Travelan(R), is pleased to announce that it has secured first orders for its Travelan(R) product in the USA.
Immuron has received its first US orders for Travelan(R) from the largest US travel medicine chain with over 240 clinics providing travel medicine services nationwide. Immuron CEO Dr Leearne Hinch said "Launching Travelan(R) in the USA is an important commercial milestone for the company, as we focus on growing Travelan revenues globally. The USA represents a significant market opportunity, and we are delighted by this initial success and the level of support and enthusiasm shown by travel clinics for Travelan(R)." Travelan is now available for sale in Australia, Canada and the USA, and is undergoing regulatory approval in China.
Travelan(R) is marketed as a dietary supplement in the US, and can be sold through pharmacists, drug stores and general stores. Immuron has implemented a direct sales model through niche retail and online channels to take advantage of the higher product margins realisable. The volume of initial US orders from travel clinics was higher than anticipated, and orders are expected to build with the potential for significant revenue as the US roll-out gains momentum. Travel clinics are an important channel for selling Travelan, as clinician recommendation of the product to people travelling to high risk destinations helps build brand awareness and consumer acceptance.
The company is also engaging with potential (nonexclusive) distribution partners for the large volume pharmacist and drug store channels to fully exploit the commercial potential of the US market.
To drive the US launch, Immuron appointed Mr Travis Robins as Director of US Sales. Travis is responsible for managing sales of Immuron's products in the USA, engaging with distributors and wholesalers, and providing technical product support to US customers. Travis is an accomplished sales executive with over 10 years' experience in sales and marketing across medical devices, biotechnology and specialty pharmaceuticals.
Immuron has developed a GMP (Good Manufacturing Practice) compliant production system that produces hyper-immune bovine colostrum powder (BCP) suitable for use as pharmaceuticals. This production system is the result of a significant body of know-how that Immuron developed over the years and is reflected in its standard operating protocols as well as aspects of the production system that are patented. The production system is capable of producing and has in fact already generated many tonnes of hyper-immune bovine colostrum powder.
Help employers find you! Check out all the jobs and post your resume.
Immuron has received its first US orders for Travelan(R) from the largest US travel medicine chain with over 240 clinics providing travel medicine services nationwide. Immuron CEO Dr Leearne Hinch said "Launching Travelan(R) in the USA is an important commercial milestone for the company, as we focus on growing Travelan revenues globally. The USA represents a significant market opportunity, and we are delighted by this initial success and the level of support and enthusiasm shown by travel clinics for Travelan(R)." Travelan is now available for sale in Australia, Canada and the USA, and is undergoing regulatory approval in China.
Travelan(R) is marketed as a dietary supplement in the US, and can be sold through pharmacists, drug stores and general stores. Immuron has implemented a direct sales model through niche retail and online channels to take advantage of the higher product margins realisable. The volume of initial US orders from travel clinics was higher than anticipated, and orders are expected to build with the potential for significant revenue as the US roll-out gains momentum. Travel clinics are an important channel for selling Travelan, as clinician recommendation of the product to people travelling to high risk destinations helps build brand awareness and consumer acceptance.
The company is also engaging with potential (nonexclusive) distribution partners for the large volume pharmacist and drug store channels to fully exploit the commercial potential of the US market.
To drive the US launch, Immuron appointed Mr Travis Robins as Director of US Sales. Travis is responsible for managing sales of Immuron's products in the USA, engaging with distributors and wholesalers, and providing technical product support to US customers. Travis is an accomplished sales executive with over 10 years' experience in sales and marketing across medical devices, biotechnology and specialty pharmaceuticals.
Immuron has developed a GMP (Good Manufacturing Practice) compliant production system that produces hyper-immune bovine colostrum powder (BCP) suitable for use as pharmaceuticals. This production system is the result of a significant body of know-how that Immuron developed over the years and is reflected in its standard operating protocols as well as aspects of the production system that are patented. The production system is capable of producing and has in fact already generated many tonnes of hyper-immune bovine colostrum powder.
Help employers find you! Check out all the jobs and post your resume.